Home > Press release

 

 

ARCHIVE PRESS RELEASE
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
Purpose First: Chiesi Publishes 2024 Sustainability Report
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants